REFERENCES
- Blum, J.L.; Jones, S.E.; Buzdar, A.U.; LoRusso, P.M.; Kuter, I.; Vogel, C.; Osterwalder, B.; Burger, H.U.; Brown, C.S.; Griffin, T. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999, 17(2), 485–493.
- Blum, J.L.; Dieras, V.; Lo Russo, P.M.; Horton, J.; Rutman, O.; Buzdar, A.; Osterwalder, B. Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 2001, 92(7), 1759–1768.
- Fumoleau, P.; Largillier, R.; Trillet-Lenoir, V.; Orfeuvre, H.; Extra, J.M.; Lesimple, T. Phase II study of capecitabine (Xeloda®) in patients with advanced breast cancer (ABC), previously treated with anthracyclines and taxanes. Breast Cancer Res Treat 2001, 69(3), 285 (Abstract 435).
- Reichardt, P.; von Minckwitz, G.; Luck, H.J.; Thuss-Patience, P.C.; Jonat, W.; Kölbl, H.; Kiebak, D.; Kuhn, W.; Flocmer, F.; Frings, S. Capecitabine: the new standard in metastatic breast cancer failing anthracycline and taxane containing chemotherapy? Mature results of a large multicenter phase II trial. Eur J Cancer 2001, 37(Suppl. 6), S191a.
- Blum, J.; Jones, S.; Buzdar, A. Capecitabine (Xeloda) in 162 patients with paclitaxel-pretreated MBC: updated results and analysis of dose modification. Eur J Cancer 2001, 37(Suppl. 6), S190a.
- O’Shaughnessy, J.; Miles, D.; Vukelja, S.; Moiseyenko, V.; Ayoub, J.P.; Cervantes, G.; Fumoleau, P.; Jones, S.; Lui, W.Y.; Mauriac, L.; Twelves, C.; Van Hazel, G.; Verma, S.; Leonard, R. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002, 20(12), 2812–2823.
- Geyer, C.E.; Forster, J.; Lindquist, D.; Chan, S.; Romieu, C.G.; Pienkowski, T.; Jagiello-Gruszfeld, A.; Crown, J.; Chan, A.; Kaufman, B.; Skarlos, D.; Campone, M.; Davidson, N.; Berger, M.; Oliva, C.; Rubin, S.D.; Stein, S.; Cameron, D. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006, 355(26), 2733–2743.
- Thomas, E.S.; Gomez, H.L.; Li, R.K.; Chung, H.C.; Fein, L.E.; Chan, V.F.; Jassem, J.; Pivot, X.B.; Klimovsky, J.V.; de Mendoza, F.H.; Xu, B.; Campone, M.; Lerzo, G.L.; Peck, R.A.; Mukhopadhyay, P.; Vahdat, L.T.; Roche, H.H. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2007, 25(33), 5210–5217.
- Kaplan, E.; Meier, P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53, 457–481.
- Seidman, A.D.; O’Shaughnessy, J.; Misset, J.L. Single-agent capecitabine: A reference treatment for taxane-pretreated metastatic breast cancer? Oncologist 2002, 7(Suppl. 6), 20–28.
- Miller, K.D.; Chap, L.I.; Holmes, F.A.; Cobleigh, M.A.; Marcom, P.K.; Fehrenbacher, L.; Dickler, M.; Overmoyer, B.A.; Reimann, J.D.; Sing, A.P.; Langmuir, V.; Rugo, H.S. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005, 23(4), 792–799.
- Miller, K.; Wang, M.; Gralow, J.; Dickler, M.; Cobleigh, M.; Perez, E.A.; Shenkier, T.; Cella, D.; Davidson, N.E. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007, 357(26), 2666–2676.
- Miles, D.; Chan, A.; Romieu, G.; Dirix, L.Y.; Cortes, J.; Pivot, X.; Tomczak, P.; Taran, T.; Harbeck, N.; Steger, G.G. Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (MBC): AVADO. ASCO Meeting Abstracts. 2008, 26(15 Suppl.), LBA1011.
- Robert, N.J.; Dieras, V.; Glaspy, J.; Brufsky, A.; Bondarenko, I.; Lipatov, O.; Perez, E.; Yardley, D.; Zhou, X.; Phan, S. RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). ASCO Meeting Abstracts. 2009, 27(15S), 1005.